Business
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
EsoGuard® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"EsoGuard® test volume increased 31 percent quarterly; 44 percent annually\nClinical data now well-positioned for final push towards broad coverage and reimbursement\nOver 50 high-volume #CheckYourFoodTube Precancer Testing Events in 2Q24, including first with upfront contracted payment\nConference call and webcast to be held today, August 12th at 8:30 AM EDT\nNEW YORK, Aug. 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( \"PAVmed\"), today provided a business update for the Company and presented financial results for the three months ended June 30, 2024.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will take place on Monday, August 12, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name \"Lucid Diagnostics Business Update\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.\nBusiness Update Highlights\n\"I am very pleased with the excellent progress Lucid has made on multiple fronts during the second quarter and recent weeks, specifically the progress made related to EsoGuard's clinical data,\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"We are now fully armed with a complete body of clinical data and well-positioned for our final push towards broad coverage and reimbursement to drive EsoGuard revenue and revenue growth.\"\nHighlights from the second quarter and recent weeks:\nFor the quarter, EsoGuard® Esophageal DNA Test revenue was $1.0M, which was flat compared to 1Q24 and represents a 514 percent annual increase from 2Q23.Lucid's CLIA-certified clinical laboratory performed 3,147 commercial EsoGuard tests in 2Q24, a single-quarter record, which represents a 31 percent increase sequentially from 1Q24 and a 44 percent annual increase from 2Q23.Released ENVET-BE clinical utility study positive data show...